Cirius Therapeutics to Present at Upcoming Healthcare Conferences

GRAND RAPIDS, Mich., March 25, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering with diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that its executives will be speaking at the following upcoming healthcare conferences:

• MedInvest Biotech & Pharma Investor Conference¹ in New York, NY on Friday, March 28.
  
  2:20 PM ET: Phase 2b-proven Clinical Candidate 0602K Under Development for Obesity/Overweight, T2D & MASH
  CEO Robert Beardsley, Ph.D., will discuss the key role of insulin resistance and opportunities in metabolic disease for 0602K.
  
  
• GLP-1-Based Therapeutics Summit² in Boston, MA, on Wednesday, April 30.
  
  9:00 AM ET: New Insulin Sensitizers as a Golden Combination With GLP-1 & Weight Loss Therapies
  CSO Jerry Colca, Ph.D., will discuss how reprogramming mitochondria by targeting the mitochondrial pyruvate carrier (MPC) with Cirius' 0602K drives metabolic changes that synergize with GLP-1 receptor agonists to improve treatment effects, including preventing the loss of skeletal muscle. Combination treatment may improve weight loss durability and patient health outcomes.
  
  5:00 PM ET: Subcutaneous Vs Oral Administration in GLP-1: Will Oral Administration Really Improve Patient Adherence?
  Dr. Colca will also participate in a panel discussing the role of oral GLP-1 therapies to improve patient adherence across the spectrum of chronic metabolic disease and facilitate combination with other oral agents including insulin sensitizers.
  
  5:30 PM ET: Forging Strategic Alliances Across Biotech, Pharma & Investors to Turbocharge Commercial & Scientific Breakthroughs in GLP-1 Development
  CEO Robert Beardsley, Ph.D., will participate in a panel discussion diving into the scientific and commercial factors of a successful partnership to develop GLP-1 combination therapies for obesity and beyond.

^1. https://www.cooley.com/events/2025/2025-03-27-medinvest-biotech-pharma-investor-conference
^2. https://glp-1-based-therapeutics.com

About Cirius
Cirius is a clinical-stage pharmaceutical company developing innovative therapies for patients suffering with diseases caused by insulin resistance, including type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, azemiglitazone potassium (0602K), is a potential best-in-class small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC Inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders.

About Azemiglitazone Potassium (0602K)
Azemiglitazone potassium has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy.  Preclinical studies also demonstrate increased lean muscle mass and function, together with marked metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), including increased brown adipose tissue ("brown fat"). Selectively targeting MPC – while avoiding PPARg activation – 0602K harnesses the real-world proven efficacy of 1^st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy.  Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other diseases.

www.CiriusTx.com

SOURCE Cirius Therapeutics